The global migraine market is estimated to reach $7.8 billion in the year 2025.
This makes the current competition interesting and contributes to the development of new drugs to treat this condition.
Although there is an opinion about the market becoming overcrowded; in my point of view, new drugs and, especially, new classes of drugs can potentially change the market, creating tough conditions for less effective drugs and contributing to market growth.
Another research published by Global Data indicates that new class of drugs - CGRP Inhibitors (calcitonin gene-related peptide inhibitors) will be the major